Accurexa, Inc. (OTCQB: ACXA) is focused on the development and commercialization of novel neurological therapies. The company’s propriety BranchPoint device was invented to deliver therapeutics, such as stem cells or gene therapy vectors, through the radial deployment of a flexible catheter to specific brain target areas through a single penetration. In an animal study completed at the University of California, San Francisco, BranchPoint demonstrated a 75 percent improvement over the current standard of care in terms of infusion reflux. For more information, visit the company’s website at www.accurexa.com.